MAPT and Schnyder corneal dystrophy: Thus, negative findings in this trial might be due to a potentially large percentage of individuals without amyloid or tau pathology, indicating other reasons for worrying about their cognitive function that might be less susceptible to dietary approaches.2,6 However, our participants with SCD were characterized according to currently accepted guidelines for SCD,1 and our intervention did not specifically target amyloid or tau.